Suppr超能文献

哮喘学童的下丘脑-垂体-肾上腺轴抑制。

Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children.

机构信息

Paediatric Endocrine Unit, Tygerberg Children’s Hospital, University of Stellenbosch, Cape Town, South Africa.

出版信息

Pediatrics. 2012 Dec;130(6):e1512-9. doi: 10.1542/peds.2012-1147. Epub 2012 Nov 12.

Abstract

BACKGROUND AND OBJECTIVE

Hypothalamic-pituitary-adrenal axis suppression (HPAS) when treating children with corticosteroids is thought to be rare. Our objective was to determine the prevalence of and predictive factors for various degrees of HPAS.

METHODS

Clinical features of HPAS, doses, adherence, asthma score, and lung functions were recorded in 143 asthmatic children. The overnight metyrapone test was performed if morning cortisol was >83 nmol/L. Spearman correlations coefficients (r) were calculated between 3 postmetyrapone outcomes and each continuous variable. A multiple linear regression model of √postmetyrapone adrenocorticotropic hormone (ACTH) and a logistic regression model for HPAS were developed.

RESULTS

Hypocortisolemia was seen in 6.1% (1.8-10.5), hypothalamic-pituitary suppression (HPS) in 22.2% (14.5-29.9), adrenal suppression in 32.3% (23.7-40.9), HPAS in 16.3% (9.3-23.3), and any hypothalamic-pituitary-adrenal axis dysfunction in 65.1% (56.5-72.9). Log daily nasal steroid (NS) dose/m(2) was associated with HPAS in the logistic regression model (odds ratio = 3.7 [95% confidence interval: 1.1-13.6]). Daily inhaled corticosteroids (ICSs) + NS dose/m(2) predicted HPAS in the univariate logistic regression model (P = .038). Forced expiratory volume in 1 second/forced vital capacity <80% was associated with HPAS (odds ratio = 4.1 [95% confidence interval: 1.0-14.8]). Daily ICS + NS/m(2) dose was correlated with the postmetyrapone ACTH (r = -0.29, P < .001). BMI (P = .048) and percent adherence to ICS (P < .001) and NS (P = .002) were predictive of √postmetyrapone ACTH (R(2) = .176).

CONCLUSIONS

Two-thirds of children on corticosteroids may have hypothalamic-pituitary-adrenal axis dysfunction. In one-third, central function had recovered but adrenal suppression persisted. Predictive factors for HPAS are NS use, BMI, and adherence to ICS and NS.

摘要

背景与目的

人们认为,儿童在接受皮质类固醇治疗时发生下丘脑-垂体-肾上腺轴抑制(HPAS)的情况很少见。我们的目的是确定不同程度 HPAS 的患病率和预测因素。

方法

对 143 例哮喘患儿的 HPAS 临床特征、剂量、依从性、哮喘评分和肺功能进行了记录。如果晨皮质醇>83nmol/L,则进行过夜甲吡酮试验。计算了 3 项甲吡酮后结果与每个连续变量之间的 Spearman 相关系数(r)。建立了 √甲吡酮后促肾上腺皮质激素(ACTH)的多元线性回归模型和 HPAS 的逻辑回归模型。

结果

低皮质醇血症发生率为 6.1%(1.8-10.5),下丘脑-垂体抑制(HPS)发生率为 22.2%(14.5-29.9),肾上腺抑制发生率为 32.3%(23.7-40.9),HPAS 发生率为 16.3%(9.3-23.3),下丘脑-垂体-肾上腺轴功能障碍发生率为 65.1%(56.5-72.9)。在逻辑回归模型中,每日鼻用皮质类固醇(NS)剂量/m2与 HPAS 相关(比值比=3.7[95%置信区间:1.1-13.6])。每日吸入皮质类固醇(ICS)+NS 剂量/m2 可预测单变量逻辑回归模型中的 HPAS(P=0.038)。1 秒用力呼气容积/用力肺活量<80%与 HPAS 相关(比值比=4.1[95%置信区间:1.0-14.8])。每日 ICS+NS/m2 剂量与甲吡酮后 ACTH 相关(r=-0.29,P<0.001)。BMI(P=0.048)和 ICS(P<0.001)和 NS(P=0.002)的依从率是预测 √甲吡酮后 ACTH 的因素(R2=0.176)。

结论

接受皮质类固醇治疗的儿童中有三分之二可能存在下丘脑-垂体-肾上腺轴功能障碍。其中三分之一的儿童中枢功能已恢复,但肾上腺抑制仍持续存在。HPAS 的预测因素包括使用 NS、BMI 以及 ICS 和 NS 的依从性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验